Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK‐ERK and NF‐κB pathways in a model of chronic myeloid leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Oncology"
DOI: 10.1002/1878-0261.12186
Abstract: The introduction of tyrosine kinase inhibitors (TKI) has transformed chronic myeloid leukemia (CML) into a chronic disease with long‐term survival exceeding 85%. However, resistance of CML stem cells to TKI may contribute to the 50%… read more here.
Keywords: cml; myeloid leukemia; tpl2; resistance ... See more keywords
Obinutuzumab in two patients suffering from immune‐mediated thrombotic thrombocytopenic purpura intolerant to rituximab
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25583
Abstract: lary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy. Leukemia. 2007;21(11):2394-2396. 5. Krysiak K, Christopher MJ, Skidmore ZL, et al. A… read more here.
Keywords: obinutuzumab two; myeloid leukemia; chronic myeloid; philadelphia chromosome ... See more keywords
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26463
Abstract: Tyrosine kinase inhibitors (TKIs) have profoundly improved the clinical outcome for patients with chronic myeloid leukemia (CML), but their overall survival is still subnormal and the treatment is associated with adverse events. In a large… read more here.
Keywords: myeloid leukemia; chronic myeloid; kinase inhibitors; patients diagnosed ... See more keywords
Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26686
Abstract: Ponatinib, the only third‐generation pan‐BCR::ABL1 inhibitor with activity against all known BCR::ABL1 mutations including T315I, has demonstrated deep and durable responses in patients with chronic‐phase chronic myeloid leukemia (CP‐CML) resistant to prior second‐generation (2G) TKI… read more here.
Keywords: chronic myeloid; leukemia; generation; phase chronic ... See more keywords
Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management
Sign Up to like & getrecommendations! Published in 2023 at "American Journal of Hematology"
DOI: 10.1002/ajh.26828
Abstract: Atypical chronic myeloid leukemia (aCML) and myelodysplastic/myeloproliferative (MDS/MPN) neoplasms, not otherwise specified (NOS), are MDS/MPN overlap neoplasms characterized by leukocytosis, in the absence of monocytosis and eosinophilia, with read more here.
Keywords: myeloid leukemia; chronic myeloid; atypical chronic; myelodysplastic myeloproliferative ... See more keywords
Change of right ventricular systolic pressure can indicate dasatinib‐induced pulmonary arterial hypertension in chronic myeloid leukemia
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.3588
Abstract: We investigated the feasibility of the clinical application of non‐invasive transthoracic echocardiography for diagnosis of pulmonary arterial hypertension induced by dasatinib (D‐PAH) in chronic myeloid leukemia (CML). read more here.
Keywords: pulmonary arterial; myeloid leukemia; arterial hypertension; chronic myeloid ... See more keywords
Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro
Sign Up to like & getrecommendations! Published in 2017 at "Cell Biology International"
DOI: 10.1002/cbin.10686
Abstract: Imatinib mesylate (IM) and other BCR‐ABL tyrosine kinase inhibitors (TKIs) have improved chronic myeloid leukemia (CML) patient survival markedly but fail to eradicate quiescent CML leukemia stem cells (LSCs). Thus, strategies targeting LSCs are required… read more here.
Keywords: cml; leukemia; chronic myeloid; stem ... See more keywords
Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death
Sign Up to like & getrecommendations! Published in 2017 at "Cancer"
DOI: 10.1002/cncr.30636
Abstract: Smoking is suspected to not only be a risk factor for chronic myeloid leukemia but an adverse prognostic factor for the disease as well. The objective of the current study was to investigate the impact… read more here.
Keywords: risk; myeloid leukemia; disease; chronic myeloid ... See more keywords
Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia
Sign Up to like & getrecommendations! Published in 2017 at "Cancer"
DOI: 10.1002/cncr.30885
Abstract: Several studies have demonstrated that approximately one‐half of patients with chronic myeloid leukemia (CML) who receive treatment with tyrosine kinase inhibitors (TKIs) and achieve and maintain a deep molecular response (DMR) are able to successfully… read more here.
Keywords: myeloid leukemia; tyrosine kinase; patients chronic; chronic myeloid ... See more keywords
Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or intolerant to prior therapy
Sign Up to like & getrecommendations! Published in 2018 at "Cancer"
DOI: 10.1002/cncr.31082
Abstract: Health‐related quality of life (HRQOL) in patients with chronic‐phase chronic myeloid leukemia (CML) is important because of the requirement for long‐term treatment. This study assessed HRQOL in bosutinib‐treated patients with Philadelphia chromosome–positive CML and resistance… read more here.
Keywords: long term; myeloid leukemia; chronic myeloid; chromosome positive ... See more keywords
Health‐related quality of life in patients with chronic myeloid leukemia receiving first‐line therapy with nilotinib
Sign Up to like & getrecommendations! Published in 2018 at "Cancer"
DOI: 10.1002/cncr.31323
Abstract: Although a wealth of efficacy and safety data is available for many tyrosine kinase inhibitors used in chronic myeloid leukemia (CML), there is a dearth of information on their impact on patients' health‐related quality of… read more here.
Keywords: receiving first; myeloid leukemia; health related; chronic myeloid ... See more keywords